Four one-year Phase 2 pilot projects will pair UConn and Yale researchers with Microsoft, Pfizer, RTX, Quantinuum and D-Wave to turn quantum research into commercial applications.
The projects target quantum-secure communications, logistics optimization, drug safety prediction and constrained optimization, using hybrid quantum-classical systems to tackle problems beyond conventional hardware limits.
One optimization track maps supply chains onto D-Wave’s Advantage2 processor, while another combines quantum annealing with classical methods to handle combinatorial problems with up to 2 million variables and constraints.
QuantumCT said the statewide effort is meant to strengthen Connecticut’s defense, manufacturing and life-sciences base while retaining specialized quantum and microelectronics talent.
The partnership was built around the NSF Regional Innovation Engines program and is one of 15 national finalists, with major federal awards due later in 2026.
Can Connecticut's new alliance solve the quantum code-breaking threat before federal deadlines hit?
Is Connecticut's quantum bet on today's hybrid systems a bridge to the future or a costly dead end?
QuantumCT Launches Four Phase 2 Quantum Pilot Projects: Connecticut’s Bid for National Leadership and NSF Innovation Engine Funding
Overview
QuantumCT, a localized technology development framework, has launched four Phase 2 pilot projects in direct response to the U.S. National Science Foundation’s Regional Innovation Engines program, which funds place-based innovation hubs to preserve national technology competitiveness. As one of 15 national finalists, QuantumCT aims to accelerate the translation of advanced quantum research into commercial solutions through strong collaboration between leading universities and industry partners. This initiative is designed to build a robust regional quantum workforce and ecosystem, aligning research with industry needs and positioning Connecticut as a leader in next-generation technology innovation.